FoRe, immunological precision
designed to move faster.
FoRe is a portable platform developed by Preciphos to perform selected high-precision immunological analyses from a reduced blood volume.
Its objective is to make selected biological information more rapidly accessible in hospital, scientific or preclinical environments, while maintaining a controlled framework of use.
Miniaturizing analysis to accelerate access to information
Six strengths that define the platform.
FoRe addresses the main limitations of centralized biological testing:
sample volume requirements, turnaround times, costs, and dependence on heavy infrastructure.
Immunological reactions performed in a highly miniaturized format, directly at the point of care.
Analysis possible from less than 50 µL of blood — designed for the most vulnerable patients.
Faster access to key biological data, with results available in under 30 minutes.
Up to 8 biomarkers or drugs quantified simultaneously, depending on the use case.
A compact and portable platform that can be deployed close to the care environment.
A potentially 2 to 4 times more affordable alternative than current standard solutions.
A platform open
to several usage environments.
FoRe is designed as an adaptable technology platform that can serve multiple fields of application, depending on the developments, validations, and partnerships undertaken.
A technology originating
from a leading scientific environment.
FoRe technology originates from ETH Zurich and is part of a development trajectory led by Preciphos with a clear ambition: to transform a scientific innovation into a deployable medtech platform.
in your context?
Preciphos offers qualified discussions with hospital, scientific, institutional, industrial or investor contacts seeking to better understand the technology, its conditions of use and its development perspectives.